October Issue: Conversion to Resection After Neoadjuvant #Gemcitabine , #Cisplatin , and #NabPaclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis
https://rdcu.be/eMq0E
1
1
0
0
October Issue: Conversion to Resection After Neoadjuvant #Gemcitabine , #Cisplatin , and #NabPaclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis
https://rdcu.be/eMq0E
SWOG S1815 shows no OS benefit for nab-paclitaxel in BTCs - Rachna T. Shroff
@rachnatshroff.bsky.social
oncodaily.com/science/rach...
#AdvancedBiliaryCancer #BTCResearch #Cancer #Medicine #GemcitabineCisplatin #JCO #ASCO #NabPaclitaxel #Health #OncoDaily #Oncology #SWOG #S1815